ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
HKD 4.99
(2.89%)
HKD 4.99
(2.89%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -364.67 Million CNY | 0.23% |
| 2022 | -402.1 Million CNY | 45.25% |
| 2021 | -734.37 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -80.46 Million HKD | 62.53% |
| 2024 Q2 | -79.77 Million HKD | 0.15% |
| 2023 Q4 | -219.01 Million HKD | -108.03% |
| 2023 FY | -401.18 Million CNY | 0.23% |
| 2023 Q3 | -105.28 Million HKD | 45.0% |
| 2023 Q2 | -191.42 Million HKD | -99.11% |
| 2023 Q1 | -96.14 Million HKD | 58.6% |
| 2022 FY | -402.1 Million CNY | 45.25% |
| 2022 Q4 | -232.22 Million HKD | -108.31% |
| 2022 Q3 | -111.48 Million HKD | 43.24% |
| 2022 Q2 | -196.39 Million HKD | 0.0% |
| 2021 FY | -734.37 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 638.12% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 140.612% |